Trial Protocol ID USOR 20326_TOL2506A_OVELIA

Trial Description

A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Carol Tweed, M.D.

Disease Types


  • Clinipace Tolmar, Inc. NCT ID

  • NCT04906395